Published in Blood Weekly, January 9th, 2003
Genmab has identified a lead candidate in this program which appears to be superior to at least one antibody product currently on the market when tested in vitro. In these laboratory studies, HuMax-TAC showed superior inhibition of IL-2 binding to the IL-2 receptor and also blocked the proliferation of activated T-cells that express the receptor and play an important role in inflammation. Other potential indications include graft versus host disease, T-cell leukemia, Hodgkin disease, and autoimmune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.